Botanix Pharmaceuticals

Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic[1] cannabinoid[2] company, focusing on the compound Cannabidiol.[3] The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex,[4] for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.

Botanix Pharmaceuticals Limited
Company typeListed Public Company
ASXBOT
IndustryBiotechnology
HeadquartersPerth, Western Australia, and Philadelphia, USA
Area served
Global
Key people
  • Vince Ippolito, President and executive chairman
  • Matt Callahan, Founder and executive director
  • Dr Stewart Washer, Director
  • Dr Bill Bosch, Chief scientific officer and executive director
  • Danny Sharp, Non-executive director
ProductsBTX 1503 | For the treatment of moderate to severe acne

BTX 1702 | For the treatment of rosacea BTX 1204A | For the treatment of moderate atopic dermatitis

BTX 1801 | For use in a variety of antimicrobial applications
Websitewww.botanixpharma.com

Research

edit

Botanix Pharmaceuticals product pipeline[5] currently[when?] includes four programs for treatment of serious skin diseases:

Dermatology

  • BTX 1503, for the treatment of moderate to severe acne
  • BTX 1702, for the treatment of rosacea
  • BTX 1204A, for the treatment of moderate atopic dermatitis

Antimicrobial

  • BTX 1801, for use in a variety of antimicrobial applications

References

edit
  1. ^ "Synthetic cannabinoids".
  2. ^ "Cannabinoid".
  3. ^ "Cannabidiol".
  4. ^ "Technology – Botanix Pharmaceuticals".
  5. ^ "Pipeline – Botanix Pharmaceuticals".
edit